VACC
Price:
$5
Market Cap:
$45.87M
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in precl...[Read more]
Industry
Biotechnology
IPO Date
2021-04-30
Stock Exchange
NASDAQ
Ticker
VACC
According to Vaccitech plc’s latest financial reports and current stock price. The company's current Enterprise Value is -47563679.00. This represents a change of 81.65% compared to the average of -26184559.95 of the last 4 quarters.
The mean historical Enterprise Value of Vaccitech plc over the last ten years is 22.98M. The current -47563679.00 Enterprise Value has changed -20797.23% with respect to the historical average. Over the past ten years (40 quarters), VACC's Enterprise Value was at its highest in in the March 2021 quarter at 326.01M. The Enterprise Value was at its lowest in in the December 2021 quarter at -206832000.00.
Average
22.98M
Median
3.77M
Minimum
-98078903.90
Maximum
206.33M
Discovering the peaks and valleys of Vaccitech plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 5.37%
Maximum Annual Enterprise Value = 206.33M
Minimum Annual Increase = -147.53%
Minimum Annual Enterprise Value = -98078903.90
Year | Enterprise Value | Change |
---|---|---|
2023 | 12.53M | -112.78% |
2022 | -98078903.90 | -147.53% |
2021 | 206.33M | 5.37% |
2020 | 3.77M | -139.05% |
The current Enterprise Value of Vaccitech plc (VACC) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
40.26M
5-year avg
22.98M
10-year avg
22.98M
Vaccitech plc’s Enterprise Value is less than Molecular Partners AG (107.67M), less than MediciNova, Inc. (61.90M), less than Anebulo Pharmaceuticals, Inc. (31.01M), less than Champions Oncology, Inc. (116.09M), less than Cyteir Therapeutics, Inc. (-20511738.00), less than Edgewise Therapeutics, Inc. (2.80B), less than Talaris Therapeutics, Inc. (511.47M), less than Adicet Bio, Inc. (-13641226.00), less than Cullinan Oncology, Inc. (591.52M), less than Vor Biopharma Inc. (39.67M), less than Tyra Biosciences, Inc. (655.85M), less than Third Harmonic Bio, Inc. (193.94M), less than C4 Therapeutics, Inc. (294.04M), less than Stoke Therapeutics, Inc. (467.23M), less than Revolution Medicines, Inc. (7.90B), less than Design Therapeutics, Inc. (323.81M), less than Achilles Therapeutics plc (-42104641.00), less than Neoleukin Therapeutics, Inc. (-6333315.00), greater than Magenta Therapeutics, Inc. (-114170976.00), less than Graphite Bio, Inc. (-15007658.00), less than CytomX Therapeutics, Inc. (55.32M), less than Instil Bio, Inc. (220.42M), less than Spero Therapeutics, Inc. (-21358605.00), less than Assembly Biosciences, Inc. (67.83M),
Company | Enterprise Value | Market cap |
---|---|---|
107.67M | $200.54M | |
61.90M | $103.98M | |
31.01M | $32.42M | |
116.09M | $112.07M | |
-20511738.00 | $108.71M | |
2.80B | $2.84B | |
511.47M | $116.44M | |
-13641226.00 | $73.64M | |
591.52M | $691.16M | |
39.67M | $59.62M | |
655.85M | $753.42M | |
193.94M | $486.63M | |
294.04M | $286.59M | |
467.23M | $614.95M | |
7.90B | $8.01B | |
323.81M | $351.62M | |
-42104641.00 | $40.33M | |
-6333315.00 | $8.20M | |
-114170976.00 | $42.44M | |
-15007658.00 | $185.19M | |
55.32M | $85.30M | |
220.42M | $141.74M | |
-21358605.00 | $50.31M | |
67.83M | $94.84M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vaccitech plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Vaccitech plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Vaccitech plc's Enterprise Value?
What is the highest Enterprise Value for Vaccitech plc (VACC)?
What is the 3-year average Enterprise Value for Vaccitech plc (VACC)?
What is the 5-year average Enterprise Value for Vaccitech plc (VACC)?
How does the current Enterprise Value for Vaccitech plc (VACC) compare to its historical average?